See more : Bénéteau S.A. (BEN.PA) Income Statement Analysis – Financial Results
Complete financial analysis of NanoString Technologies, Inc. (NSTG) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of NanoString Technologies, Inc., a leading company in the Medical – Instruments & Supplies industry within the Healthcare sector.
- Alleghany Corporation (Y) Income Statement Analysis – Financial Results
- Xiangtan Electric Manufacturing Co. Ltd. (600416.SS) Income Statement Analysis – Financial Results
- Hokkoku Financial Holdings, Inc. (7381.T) Income Statement Analysis – Financial Results
- Canna-Global Acquisition Corp (CNGLW) Income Statement Analysis – Financial Results
- Urb-it AB (publ) (URBIT.ST) Income Statement Analysis – Financial Results
NanoString Technologies, Inc. (NSTG)
About NanoString Technologies, Inc.
NanoString Technologies, Inc. develops, manufactures, and sells tools for scientific and clinical research in the fields of genomics and proteomics in the Americas, Europe, the Middle East, and the Asia Pacific. The company offers nCounter Analysis System, an automated, multi-application, digital detection, and counting system. It provides nCounter MAX and FLEX systems that include Prep Station, an automated liquid handling component that processes and prepares samples for data collection; and nCounter Digital Analyzer, which collects data from samples by taking images of the immobilized fluorescent reporters in the sample cartridge and processing the data into output files. The company also offers nCounter SPRINT Profiler, an instrument that provides liquid handling steps and the digital analysis through use of a microfluidic cartridge; and nSolver Analysis Software, a data analysis program that enables researchers to check, normalize, and analyze their data. In addition, it provides custom CodeSets; panels with oncology, immunology and infectious disease, and neuroscience applications. Further, the company offers Master Kits, such as ancillary reagents and plasticware to setup and process samples in the nCounter Prep Station and nCounter Digital Analyzer; and Prosigna molecular diagnostic test kits. The company is also developing GeoMx DSP system to enable the field of spatial genomics. It has collaboration with Lam Research Corporation for the research and development of Hyb & Seq technologies; Celgene Corporation for developing LymphMark, an in vitro diagnostic for the treatment of diffuse large B-cell lymphoma; and Parker Institute for Cancer Immunotherapy to develop CAR-T regimens that enhances patient outcomes for various types of cancer. NanoString Technologies, Inc. was incorporated in 2003 and is headquartered in Seattle, Washington.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2001 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 127.26M | 145.09M | 117.32M | 125.57M | 106.73M | 114.91M | 86.49M | 62.67M | 47.59M | 31.40M | 22.97M | 17.80M | 11.73M | 34.42M |
| Cost of Revenue | 65.48M | 68.30M | 52.41M | 44.04M | 36.33M | 31.88M | 30.25M | 26.13M | 21.15M | 15.01M | 12.36M | 9.78M | 9.13M | 21.12M |
| Gross Profit | 61.79M | 76.78M | 64.91M | 81.53M | 70.40M | 83.03M | 56.24M | 36.54M | 26.44M | 16.39M | 10.61M | 8.02M | 2.60M | 13.30M |
| Gross Profit Ratio | 48.55% | 52.92% | 55.33% | 64.93% | 65.96% | 72.26% | 65.03% | 58.31% | 55.56% | 52.21% | 46.19% | 45.07% | 22.18% | 38.64% |
| Research & Development | 70.84M | 69.50M | 62.86M | 68.04M | 61.60M | 46.89M | 34.72M | 24.60M | 21.40M | 14.98M | 11.64M | 8.99M | 7.55M | 19.09M |
| General & Administrative | 133.83M | 110.70M | 86.70M | 90.50M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 9.30M | 4.80M | 3.40M | 5.70M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 143.13M | 115.50M | 90.10M | 96.20M | 78.20M | 74.33M | 62.70M | 53.19M | 51.06M | 29.91M | 15.49M | 9.53M | 8.03M | 36.90M |
| Other Expenses | -1.92M | -20.00K | -971.00K | -929.00K | -1.66M | 183.00K | -515.00K | -389.00K | -147.00K | -66.00K | -29.00K | 80.00K | 254.00K | 0.00 |
| Operating Expenses | 213.97M | 185.01M | 152.95M | 164.23M | 139.79M | 121.22M | 97.42M | 77.78M | 72.47M | 44.89M | 27.12M | 18.52M | 15.57M | 55.98M |
| Cost & Expenses | 279.45M | 253.31M | 205.36M | 208.27M | 176.13M | 153.10M | 127.67M | 103.91M | 93.62M | 59.90M | 39.48M | 28.30M | 24.70M | 77.10M |
| Interest Income | 2.41M | 649.00K | 1.74M | 2.82M | 1.33M | 809.00K | 390.00K | 233.00K | 272.00K | 68.00K | 21.00K | 10.00K | 29.00K | 0.00 |
| Interest Expense | 7.54M | 7.49M | 15.41M | 8.49M | 7.43M | 6.15M | 5.67M | 4.02M | 4.14M | 1.94M | 804.00K | 599.00K | 94.00K | -1.89M |
| Depreciation & Amortization | 492.00K | 629.00K | 773.00K | 1.89M | 4.07M | 3.35M | 2.98M | 2.38M | 1.54M | 1.78M | 1.95M | 1.45M | 972.00K | 0.00 |
| EBITDA | -143.58M | -101.73M | -88.05M | -82.70M | -65.65M | -34.84M | -38.32M | -39.02M | -44.31M | -26.51M | -14.96M | -8.88M | -11.70M | -42.68M |
| EBITDA Ratio | -119.20% | -74.16% | -74.39% | -64.36% | -65.32% | -32.38% | -47.75% | -66.06% | -96.44% | -90.74% | -63.42% | -50.29% | -99.89% | -123.99% |
| Operating Income | -152.18M | -108.23M | -88.05M | -82.70M | -69.39M | -38.20M | -41.18M | -41.24M | -46.02M | -28.50M | -16.51M | -10.50M | -12.97M | -42.68M |
| Operating Income Ratio | -119.58% | -74.59% | -75.05% | -65.86% | -65.02% | -33.24% | -47.61% | -65.81% | -96.70% | -90.75% | -71.86% | -58.97% | -110.59% | -123.99% |
| Total Other Income/Expenses | -7.04M | -6.86M | -21.78M | 42.27M | -7.76M | -5.16M | -5.80M | -4.17M | -4.02M | -784.00K | -1.20M | -436.00K | 204.00K | -1.44M |
| Income Before Tax | -159.23M | -115.09M | -109.83M | -40.43M | -77.15M | -43.36M | -46.97M | -45.42M | -50.04M | -29.28M | -17.71M | -10.93M | -12.77M | -44.12M |
| Income Before Tax Ratio | -125.12% | -79.32% | -93.61% | -32.20% | -72.28% | -37.73% | -54.31% | -72.47% | -105.14% | -93.24% | -77.08% | -61.42% | -108.85% | -128.17% |
| Income Tax Expense | 317.00K | 167.00K | 253.00K | 269.00K | 249.00K | 204.00K | 116.00K | 166.00K | 2.45M | 99.00K | 775.00K | 679.00K | 348.00K | 5.00K |
| Net Income | -159.54M | -115.25M | -110.08M | -40.70M | -77.40M | -43.56M | -47.09M | -45.58M | -50.04M | -29.28M | -17.71M | -10.93M | -12.77M | -44.11M |
| Net Income Ratio | -125.37% | -79.44% | -93.83% | -32.41% | -72.52% | -37.91% | -54.45% | -72.74% | -105.14% | -93.24% | -77.08% | -61.42% | -108.85% | -128.16% |
| EPS | -3.44 | -2.54 | -2.82 | -1.18 | -2.78 | -1.84 | -2.34 | -2.40 | -2.80 | -3.83 | -1.93 | -1.19 | -1.59 | -0.95 |
| EPS Diluted | -3.44 | -2.54 | -2.82 | -1.18 | -2.78 | -1.84 | -2.34 | -2.40 | -2.80 | -3.83 | -1.93 | -1.19 | -1.59 | -0.95 |
| Weighted Avg Shares Out | 46.41M | 45.30M | 39.08M | 34.59M | 27.88M | 23.73M | 20.12M | 19.03M | 17.84M | 7.64M | 9.17M | 9.17M | 8.02M | 46.66M |
| Weighted Avg Shares Out (Dil) | 46.41M | 45.30M | 39.08M | 34.59M | 27.88M | 23.73M | 20.12M | 19.03M | 17.84M | 7.64M | 9.17M | 9.17M | 8.02M | 46.66M |
NanoString Technologies Releases Operating Results for First Quarter of 2022
NanoString to Release First Quarter 2022 Operating Results and Host Conference Call on Tuesday, May 10, 2022
NanoString Appoints Dr. Teresa Foy to Board of Directors
NanoString stock plunges after revenue warning, but analyst says selloff appears 'way overdone'
NanoString Technologies Announces Preliminary Revenue for First Quarter of Fiscal Year 2022
NanoString Technologies Announces Preliminary Revenue for First Quarter of Fiscal Year 2022
NanoString Highlights Spatial Biology Research at the 2022 American Association of Cancer Research (AACR) Conference
NanoString Launches New nCounter Pro Analysis System
Does NanoString (NSTG) Have the Potential to Rally 117% as Wall Street Analysts Expect?
NanoString Technologies' (NSTG) CEO Brad Gray on Q4 2021 Earnings Call Transcript
Source: https://incomestatements.info
Category: Stock Reports